The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology.
Nat Med
; 27(9): 1518-1524, 2021 09.
Article
in English
| MEDLINE | ID: covidwho-1402106
ABSTRACT
The current coronavirus disease 2019 (COVID-19) pandemic is the first to apply whole-genome sequencing near to real time, with over 2 million severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) whole-genome sequences generated and shared through the GISAID platform. This genomic resource informed public health decision-making throughout the pandemic; it also allowed detection of mutations that might affect virulence, pathogenesis, host range or immune escape as well as the effectiveness of SARS-CoV-2 diagnostics and therapeutics. However, genotype-to-phenotype predictions cannot be performed at the rapid pace of genomic sequencing. To prepare for the next phase of the pandemic, a systematic approach is needed to link global genomic surveillance and timely assessment of the phenotypic characteristics of novel variants, which will support the development and updating of diagnostics, vaccines, therapeutics and nonpharmaceutical interventions. This Review summarizes the current knowledge on key viral mutations and variants and looks to the next phase of surveillance of the evolving pandemic.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Genome, Viral
/
Molecular Epidemiology
/
Epidemiological Monitoring
/
SARS-CoV-2
/
COVID-19
Type of study:
Observational study
/
Prognostic study
/
Systematic review/Meta Analysis
Topics:
Vaccines
/
Variants
Limits:
Humans
Language:
English
Journal:
Nat Med
Journal subject:
Molecular Biology
/
Medicine
Year:
2021
Document Type:
Article
Affiliation country:
S41591-021-01472-w
Similar
MEDLINE
...
LILACS
LIS